Physician profile
Melanie K Hall
NPI 1851602569
$9,528.80
in general payments reported to CMS, 2019-2025
41 companies · $1,587 in 2025
The $1,587 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,976 · 2020: $1,101 · 2021: $1,122 · 2022: $1,235 · 2023: $1,159 · 2024: $1,348 · 2025: $1,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,094.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,116.54 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $1,026.00 | 2019-2025 | |
| Abbvie INC. | $992.50 | 2019-2025 | |
| Novo Nordisk INC | $881.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $844.68 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $797.43 | 2019-2025 | Xifaxan |
| Allergan, INC. | $431.55 | 2019-2020 | |
| Lilly USA, LLC | $378.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $338.52 | 2019-2025 | Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $289.07 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.64 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $217.26 | 2019-2024 | |
| Corium, LLC | $207.34 | 2022-2025 | Azstarys |
| Amarin Pharma, INC. | $200.00 | 2019-2022 | |
| Exact Sciences Corporation | $181.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.